Maraviroc Waymade

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral tablet for oral use. It treats treatment‑experienced HIV‑1 infection with CCR5‑tropic virus, usually in combination with other antiretrovirals.

GNH USA supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is a CCR5‑targeting antiretroviral used in the management of HIV‑1 infection that utilizes the CCR5 co‑receptor pathway. - Treatment‑experienced HIV‑1 infection with CCR5‑tropic virus: achieves viral suppression when added to a background regimen. - Combination antiretroviral therapy for HIV‑1: contributes to overall reduction of viral load. - Confirmed CCR5‑tropic HIV‑1 infection in any disease stage: helps maintain immune function alongside other agents.

Common Side Effects: - Headache: mild to moderate discomfort reported by many patients. - Nausea: occasional upset stomach, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Fatigue: feeling of tiredness without exertion. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Liver injury: signs of hepatitis or elevated enzymes. - Severe allergic reaction: swelling, breathing difficulty, or hives. - Depression or mood changes: new or worsening psychiatric symptoms. - QT interval prolongation: potential cardiac rhythm disturbances. - Stevens‑Johnson syndrome: rare but severe skin reaction.

Before initiating therapy, clinicians should consider the following precautions: - Liver function monitoring: assess baseline enzymes and repeat periodically. - Cardiovascular assessment: evaluate for existing heart disease or arrhythmias. - Psychiatric evaluation: screen for depression or suicidal ideation. - Hypersensitivity review: avoid in patients with known Maraviroc allergy. - Pregnancy counseling: discuss potential risks and benefits; category B. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Maraviroc may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Maraviroc exposure. - Protease inhibitors boosted with ritonavir: may increase plasma levels excessively. - Certain anticonvulsants (e.g., phenobarbital): lower therapeutic effect. Moderate Interactions (Monitor Closely): - Statins (simvastatin, lovastatin): increased risk of myopathy. - Antacids containing aluminum or magnesium: may affect absorption. - Warfarin: monitor INR for potential anticoagulation changes.